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The continual introduction of a large number of new psychoactive substances, along with
the large turnover of these substances, necessitates the development of non-targeted
detection strategies to keep pace with the ever-changing drug market. The production of
certified reference materials often lags behind the introduction of new substances to the
market, therefore these detection strategies need to be able to function without relying
on reference materials or library spectra. Synthetic opioids have recently emerged as a
drug class of particular concern due to the health issues caused by their incredibly high
potency. A common method which has been used for non-targeted analysis in the past
involves the identification of common product ions formed as a result of the fragmentation
of the parent molecule. These common fragments can then potentially be used as
markers to indicate the presence of a particular class of compounds within a sample.
In this study, standards of a number of different synthetic opioids, including 14 fentanyl
derivatives, 7 AH series opioids, 4U series opioids, 4W series opioids and MT-45, were
subjected to collision-induced dissociation studies to determine how the compounds
fragment. The spectra obtained from these studies included a number of diagnostic
fragments common to the different opioid classes that, when used in combination, show
potential for use as class predictors. By using simple data processing techniques, such
as extracted ion chromatograms, these diagnostic product ions identified can be applied
to a non-targeted screening workflow.
Keywords: synthetic opioids, collision-induced dissociation, non-targeted analysis, high-resolution mass
spectrometry (HRMS), new psychoactive substances (NPS)
INTRODUCTION
The term “opioid” literally means “opium-like substance.” Opium is the dried juice of the opium
poppy, Papaver Somniferum, which has been used for the relief of pain for thousands of years
(Ballantyne and LaForge, 2007). The actions of the opiates mirrors the actions of endogenous
opioid peptides, such as endorphins, enkephalins and dynorphins, which exist within the central
and peripheral nervous system as neurotransmitters and neuromodulators (Holden et al., 2005).
Synthetic opioids are man-made compounds that act on the opioid receptors in the brain and
mimic the effects of natural opiates, such as morphine and codeine (World Health Organisation,
2011). While there are a number of synthetic opioids known to forensic toxicologists, such as
methadone, levomethorphan and pethidine, two groups have recently come under increased
scrutiny, namely non-pharmaceutical fentanyls (NPFs), which are fentanyl derivatives that are
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obtained or synthesized illicitly, and novel synthetic opioids
(NSOs). While there can be some overlap between these
classifications, NSOs usually refer to the newer classes of opioids,
such as the AH, U andW series’, which were originally developed
to act as new opioid agonists, but never brought to the market for
human use (Lucyk and Nelson, 2017). Many of these compounds
have recently emerged onto the illicit drug market. The United
Nations Office on Drugs and Crime (UNODC) have identified
opioids as the class of compounds which cause the most harm,
accounting for 76% of all deaths attributed to drug use worldwide
in 2016, with fentanyl derivatives alone accounting for 30% of
all deaths in the United States (United Nations Office on Drugs
Crime, 2018). In addition, there is an increasing trend of fentanyl
derivatives, and other synthetic opioids, being mixed into illicit
drugs, or being sold as prescription opioids. Figure 1 shows the
chemical structures of the synthetic opioids investigated in this
study grouped into subclasses based on their structural features.
Individual structures for each of these opioids can be found
in Figures S1–S4.
The continuous introduction of a large number of new
psychoactive substances (NPS), along with the lack of certified
reference materials (CRMs) for many of these compounds,
highlights the inadequacy of traditional targeted screening
methods to detect these substances (Pasin et al., 2017b). In
particular, many synthetic opioids may not be detected by
traditional approaches to illicit drug analysis, and many routine
analyses do not screen for these compounds (Breindahl et al.,
2017). This may be due to numerous factors, including a
lack of cross-reactivity with traditional immunoassay screening
methods and data for these compounds not being available in
the mass spectral libraries that are used for drug screening
(Mohr et al., 2016). To combat this, the aim of non-
targeted analysis is to identify compounds from samples where
the molecular content is unknown (Knolhoff and Croley,
2016). Since illicit drug seizures are, by their very nature,
unknown entities, this approach to their analysis provides some
obvious advantages.
The use of high-resolution mass spectrometry (HRMS) has
been investigated for non-targeted analysis due to its ability
to be operated in data-independent acquisition (DIA) modes
in addition to traditional data-dependent acquisition (DDA)
modes (Remane et al., 2016; Pasin et al., 2017b). While DIA
has been shown to be capable of detecting more compounds
at lower concentration than DDA (Arnhard et al., 2015), a
challenge arises due to the production of “chimeric spectra.” DIA
methods fragment all precursor ions simultaneously, producing
a spectrum that includes product ions from all precursor ion
subjected to CID (Oberacher and Arnhard, 2016; Pasin et al.,
2017b). This means that the software cannot associate product
ions with their correct precursor ions. It has been suggested
that deconvolution algorithms may be used to exploit the
full potential of DIA data (Oberacher and Arnhard, 2016),
however the use of DDA may be useful in situation where rapid
identification of product ions related to specific precursor ions
is required.
The main advantage of HRMS over other mass spectrometric
methods is its ability to differentiate between ions and losses that
have the same nominal mass. For example, the loss of an NH3
molecule or an –OH group would equate to the same nominal
mass change of 17 Da. This change may be indistinguishable
using lower resolution MS techniques. If an MS technique
with a high enough mass resolution was used, however, the
accurate masses for those fragments of 17.0265 and 17.0027
Da respectively could be determined and therefore the losses
differentiated. The effectiveness of collision-induced dissociation
(CID) data for the development of non-targeted detection
strategies has been previously demonstrated for different drug
classes (Pasin et al., 2017a).
While fragmentation patterns have been proposed in the
literature for various individual opioids, mainly fentanyl
derivatives (Ohta et al., 1999; Lurie and Iio, 2009; Rittgen et al.,
2012; Kronstrand et al., 2014; Patton et al., 2014; Breindahl
et al., 2017; Fabregat-Safont et al., 2017; Helander et al., 2017;
Rojkiewicz et al., 2017), there is a need for an overview of the CID
pathways for all synthetic opioids to facilitate broad-spectrum
opioid screening. Noble et al. (2017) previously investigated the
use of HRMS data collected in DIA mode to identify 50 fentanyl
analogs without the use of CRMs. In this study, the identification
of common CID pathways is expanded to include both NPFs
and NSOs. Additionally, the application of this information to
non-targeted screening methods will be discussed.
MATERIALS AND METHODS
Solvents and Reagents
All solvents used were liquid chromatography-mass
spectrometry (LC-MS) grade. Acetonitrile, ethyl acetate and
methanol were obtained from Merck (Darmstadt, Germany).
Ammonium acetate and trichloroacetic acid were obtained from
Sigma-Aldrich (Castle Hill, Australia). Acetic acid was obtained
from Ajax Chemicals (Sydney, Australia). Ultrapure-grade
water was obtained from a Smart2Pure ultra-pure water system
(Thermo Scientific, Langenselbold, Hungary).
Opioids Standards
Fentanyl citrate was purchased from Sigma-Aldrich (Castle
Hill, NSW). Hydrochloride salts of acetyl fentanyl, 4-
fluoroisobutyryl fentanyl, meta-fluoro fentanyl, AH-7921,
AH-8529, AH-8533, U-51754, and W-19, along with neat
solids of AH-7959, AH-8532, AH-8507, U-49900, and U-
50488, were purchased from Sapphire Bioscience (Redfern,
NSW). Hydrochloride salts of furanyl fentanyl, acryl fentanyl,
4-methoxybutyryl fentanyl, valeryl fentanyl, butyryl fentanyl,
U-47700, and W-18, along with a neat solid of W-15 and
MT-45 dihydrochloride hydrate, were purchased from Chiron
Chemicals (Hawthorn, VIC). Remifentanil hydrochloride was
purchased from GlaxoSmithKline (Boronia, VIC). Citrate
salts of carfentanil, sufentanil and α-methyl fentanyl, along
with alfentanil hydrochloride, were purchased from Janssen
Pharmaceuticals (North Ryde, NSW).
Sample Preparation
Drug standards were obtained as methanolic standards of
varying concentrations. All opioid samples for the CID study
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FIGURE 1 | General chemical structure of fentanyls (A), AH series opioids (B), W series opioids (C), U series opioids with (D), and without (E) a methylene spacer and
MT-45 (F).
were diluted in methanol to a concentration of 10µg/mL. Ten
microliter of each solution was evaporated to dryness under
nitrogen, before being reconstituted in methanol and a 10mM
ammonium acetate (pH 4) buffer to give a final concentration
of 1µg/mL for analysis. All samples were refrigerated
until analysis.
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A spiked sample of equine plasma was prepared to test
the application of the identified diagnostic product ions to a
non-targeted screening workflow. A mixed standard containing
fentanyl, acetyl fentanyl, AH-7921 and U-50488 was made with
a concentration of 200 ng/mL in methanol. Two mL of blank
equine plasma was spiked with the mixed standard to give
concentrations ranging from 10 to 0.01 ng/mL. A blank sample
was also prepared for extraction. The proteins were precipitated
out of the samples by the addition of 200 µL of trichloroacetic
acid (10% in H2O) and the pH of the samples was adjusted to 3–
3.5 using hydrochloric acid. The samples were then centrifuged
at 1,500 g for 15min. Following centrifugation, the samples
were extracted using XTRACKT R© Gravity Flow DAU Extraction
Columns (UCT Inc., Bristol, United States). The cartridges were
first conditioned with 3mL of methanol, followed by 3mL of
purified water. The samples were then loaded and the cartridges
washed with 3mL of 0.1M acetic acid, before being dried
under positive pressure. Three mL of methanol was run through
the cartridges, which were dried again under positive pressure.
Finally, the samples were eluted using 3mL of an elution solvent
containing 3% ammonia and 0.5% methanol in ethyl acetate.
One drop of 0.1M methanolic hydrochloric acid was added
to the samples before the solvent was evaporated under nitrogen
at 60◦C. The samples were then reconstituted with one drop of
methanol and 100 µL of an ammonium acetate buffer (pH 3.9),
before being transferred to a vial for analysis.
Instrumental Analysis
Chromatographic separation was achieved using an Agilent
Technologies (Santa Clara, CA, USA) 1290 Infinity II UHPLC,
consisting of a high speed pump (G7120A), multisampler
(G7167B) and thermostat and column compartment (G1316A,
35◦C) coupled to an Agilent 6545 quadrupole time-of-flight mass
spectrometer (QTOF-MS). All data acquisition was conducted
using Agilent MassHunter Workstation (Version B.06.01). A
sample volume of 5 µL was injected onto a Phenomenex
(Torrance, CA, USA) Gemini 110 Å C18 LC column (2× 50mm,
5µm particle size) using a gradient elution method with a flow
rate of 0.5 mL/min and a total analysis time of 11.5min. Mobile
phase A consisted of a 10mM ammonium acetate (pH 9) buffer
and mobile phase B consisted of 0.1% acetic acid in acetonitrile.
Initial mobile phase composition was 99% A, which was held for
2min before being decreased linearly to 20% A over 6.5min. The
mobile phase was then returned to 99% A over 3 min.
The QTOF-MS was operated in positive electrospray
ionization mode (ESI+) with capillary and fragmentor voltages
of 3,500 and 100V, respectively. An Auto-MS/MS (data-
dependent) acquisition mode was used with mass ranges of
100–1,000 m/z for MS and 50–500 m/z for MS/MS and a scan
rate of 10 spectra/s for both. A preferred precursor ion table was
populated with the corresponding [M + H]+ values for each
opioid standard and the acquisition method was set to use the
preferred list only for MS/MS analysis. CID experiments were
performed using collision energies (CE) of 10, 20 and 40 eV in
separate experiments, with nitrogen as the collision gas.
For the spiked plasma samples, the QTOF was operated in
ESI+ mode with capillary and fragmentor voltages of 3,500 and
100V, respectively. An AllIonsMS (DIA) data acquisition mode
was used with a mass range of 35–1,000 m/z. Spectra were
obtained with an acquisition rate of 10 spectra/s and CEs of 10,
20, and 40 eV were used for CID.
All data acquired was processed using Agilent MassHunter
Qualitative Analysis Software (Version B.07.00). The Find by
Auto-MS/MS function was used to obtain MS/MS spectra for
all precursor ions selected for CID experiments. All MS/MS
spectra obtained from the analyzed standards can be found in
the supplementary material (Figures S5–S31). For the spiked
plasma samples, extracted ion chromatograms (EIC or XIC) were
created for a number of diagnostic product ions identified from





The generic structure of fentanyl (Figure 1, structure A) shows
many different sites that can be altered to produce various
analogs. This can lead to different CID pathways being observed
depending on the position of substituents. While this can make
it difficult to identify common fragments, some overall patterns
can be observed for the different sub-groups of NPFs. While a
phenylethyl group is the most common substituent found at R1,
some analogs contain different tails, including ester groups and
heterocyclic rings. Additionally, substitution at the C9 position of
the piperidine ring (R3) can also be found in someNPFs. Figure 2
highlights some common fragment ions that can be found from
NPFs containing differing functional groups at these locations.
The main fragments present in the MS2 of these compounds
may arise from the loss of either the C9 side chain (R3) or
the phenylamide group, resulting in fragments 1a and 1b,
respectively. Evidently the exact masses of these resultant product
ions would be highly dependent on the various functional groups
present in the structure, especially the tail group at R1. The other
common product ions found in this subclass of compounds, 1c,
may arise from the inter-ring cleavage of the piperidine ring.
Similarly to 1a and 1b, the exact mass of this fragment will
vary depending on the functional group present at R1. While the
differing masses of the product ions formed is not ideal from a
non-targeted screening perspective, understanding the pattern of
fragmentation that the molecules undergo is important to help
elucidate the structure of possible unknown compounds.
As mentioned previously, the most common functional group
found at R1 is an aromatic ring, causing the compound to
have a phenylethyl tail off the piperidine ring. Consequently,
the most common points of modification between the different
derivatives are the R2 and R4 groups (Figure 1, structure A).
Figure 3 presents the common product ions identified when this
core structure is present and there is no additional side chain
present on the piperidine ring (R3). The first common product
ion can be found at an m/z of 105.0704 which is representative
of a methyl-substituted tropylium ion (2a). This fragment is
very common for alkyl-substituted benzenes and will often break
down to form the methyl-substituted aromatic cyclopentadienyl
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FIGURE 2 | Proposed structures of fragments observed for NPFs containing differing tails and C9 side chains, showing molecular ion (1) and common product
ions (1a−1c).
cation, fragment 2b, with an m/z of 79.0548 (Pavia et al., 2014).
While these product ions are quite common, and therefore not
specific to NPFs, their presence in addition to other common
fragments can help confirm the presence of these compounds.
Product ions 2c and 2dmay be formed from the cleavage between
the nitrogen and the carbonyl group of the amide side chain.
The m/z of fragment 2c may change with substitution of the
aromatic ring, however many derivatives have an unsubstituted
aromatic ring, leading to a product ion with an m/z of 281.2018.
The functional groups at R2 on fragment 2d are much more
varied, leading to different m/z values being observed, however
the loss between the molecular ion and fragment 2c can give an
indication of the expected m/z for fragment 2d. The further loss
of the nitrogen and aromatic ring from fragment 2c gives rise
to fragment 2e, with an m/z of 188.1439. While it has not been
confirmed whether this product ion is formed directly from the
fragmentation of the molecular ion, or if further fragmentation
of another product ion has occurred, it is not of great importance
for non-targeted screening purposes. The important information
in this case is that a product ion with the observed m/z is present
in the samples analyzed. The loss of the phenylethyl tail and the
collapse of the piperidine ring leads to the formation of fragment
2f. Once again, the exact m/z of this fragment will vary due to the
presence of the amide side chain, which can vary dramatically.
Finally, fragment 2g can form from the collapse of the piperidine
ring and cleavage between the nitrogen and carbonyl group of
the amide side chain. Similarly to fragment 2c, fragment 2g may
vary with substitution of the aromatic ring, however it is most
commonly found with an m/z of 146.0970 when no substituent
is present. Interestingly, the two fluorine-containing derivatives
analyzed in this study (4-fluoroisobutyryl fentanyl A5 and meta-
fluoro fentanyl A9, Figure 1) both showed fragments at m/z
146.0970. This indicates that fluorine may have been lost before
the formation of this fragment, as no corresponding fragment
was observed at m/z 165.0954 which would have been expected
for the fluorine-substituted product ion.
While all the common product ions identified were not
observed for all NPFs, the large number identified meant that
a combination of multiple common fragments were present
across all derivatives analyzed. The presence of a combination of
these common fragments in an unknown sample can provide a
strong indication that an NPF may be present within the sample.
The core structure displayed by these compounds, especially
those related to structure 2, allows for the use of a smaller
number of fragments to identify the presence of a broad range of
compounds. More importantly, some of the fragments presented
in Figure 3 have little or no variation in their m/z, regardless
of the alterations made to core structure. This means that these
product ions could potentially be used to screen for previously
unknown derivatives, provided that they contain the same core
structure. This is of great importance for non-targeted analysis,
since the structures of NPFs are unknown.
AH Series Opioids
The AH series of synthetic opioids fragment quite predictably,
breaking down from the cyclohexane ring toward the aromatic
group (Figure 4, structure 3). The first product ion is generated
from the loss of the amine side chain attached to the cyclohexane
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FIGURE 3 | Proposed structures of fragments observed for NPFs containing a phenylethyl tail and lacking a C9 side chain, showing molecular ion (2) and common
product ions (2a−2g).
ring to form 3a. While the mass loss caused by this fragmentation
can vary depending on the structure of the amine side chain,
most AH series opioids have one or two Cl substituents on the
aromatic group, resulting in product ion 3a having an m/z of
250.0999 (35Cl), 252.0969 (37Cl), 284.0609 (35Cl/35Cl), 286.0580
(35Cl/37Cl), or 288.0550 (37Cl/37Cl), respectively. The next major
fragments form as a result of the loss of the cyclohexane group
and shortening of the amide side chain, giving rise to product
ions 3b and 3c, respectively. The loss of the amine group and
finally the carbonyl group attached to the aromatic ring results
in the formation of the final characteristic fragments, 3d and
3e, respectively. Fragments 3b–3e may have different m/z values
depending on whether they contain one or two Cl substituents,
similar to 3a, however all the compounds within this subclass of
synthetic opioids will present a fragment with one of these m/z
values. The common m/z produced by these fragments highlight
the possibility of using them as targets for screening techniques
to detect the presence of this series of NSOs.
U Series Opioids
The U series compounds which do not contain a methylene
spacer (Figure 1, structure E) are constitutional isomers of the
compounds within the AH series (Figure 1, structure B). This
means that, while the structures of the fragments are slightly
different, they have identical theoretical m/z values. When it
comes to non-targeted analysis, this can be a double-edged
sword. On the one hand, having the same m/z values means
that a smaller number of common product ions can be used
to capture a broader range of compounds. Conversely, the
presence of multiple fragment ions with the same m/z reduces
the effectiveness of techniques such as class prediction models,
making it difficult to determine the identity of these isomers on
their fragmentation pattern alone.
The U series compounds which do contain a methylene spacer
(Figure 1, structure D) fragment in a similar manner, however
the presence of the spacer changes the m/z of the product ions
observed, allowing them to be distinguished from other NSOs.
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FIGURE 4 | Proposed structures of fragments observed for AH series opioids, showing molecular ion (3) and common products ions (3a−3e).
Figure 5 provides an overview of the major common fragments
observed from the CID of these compounds. Similarly to the AH
series compounds, the loss of the amine group on the cyclohexane
ring may produce fragment 4a. All the compounds analyzed in
this study containing the additional methylene spacer had two Cl
substituents on the aromatic ring, leading to fragment 4a having
a theoretical m/z of 298.0766 (35Cl/35Cl), 300.0736 (35Cl/37Cl),
and 302.0707 (37Cl/37Cl). Changing the functional groups on the
aromatic ring would lead to different m/z values being observed
for this fragment, as was seen with the AH series compounds,
however the two Cl groups appears to be the most common
structure found. The subsequent loss of the cyclohexane ring and
the amide group produced fragments 4b and 4c, respectively.
Once again, these fragments may have different m/z values,
dependent on the functional groups present on the aromatic ring,
however the fragmentation pattern remains consistent.
W Series Opioids
The W series of synthetic opioids do not have an extensive
fragmentation pattern, with only a few product ions being
detected. Figure 6 provides an overview of the common fragment
ions proposed. This series of compounds only has one main area
of structural variation, meaning that some product ions will have
the same m/z regardless of which derivative is analyzed. The first
product ion identified, 5a, comes from the loss of one of the
aromatic groups attached to the 6-membered heterocyclic ring
and contains the differing functional group. This means that the
exact m/z of this fragmentmay vary depending on the substituent
attached to the aromatic ring. The remaining two fragments, 5b
and 5c, respectively, arise from the isolation of the heterocyclic
ring and the breaking of the sulfur-nitrogen bond. Given that
these fragments do not have any varying functional groups,
fragment 5b will have a consistent m/z of 111.0922. Fragment 5c
will have theoretical m/z values of 174.9621 (35Cl) and 176.9591
(37Cl). While there may not be as many common fragment ions
within this series, there are still some masses which may prove
useful targets for the development of screening methods.
MT-45
MT-45 is a synthetic opioid that does not fit into any of the
other defined classes. The fragmentation of this compound was
studied and a number of product ions identified (Figure 7).
The first fragmentation involves the cleavage of the bond
between the piperazine ring and the dibenzene side chain. This
gives rise to product ions 6a and 6b which can be observed
at m/z 181.1017 and 169.1705, respectively. The subsequent
cleavage occurs between the piperazine and cyclohexane rings
of 6b, forming product ions 6c and 6d with m/z 87.0922 and
83.0861, respectively. While this fragmentation pattern is for
a single compound, there is a possibility for the development
of additional derivatives based on this core structure. If such
derivatives are encountered, the product ions observed can be
compared to those presented in Figure 7 to identify which ones
can be considered diagnostic ions for the new subclass.
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FIGURE 5 | Proposed structures of fragments observed for U series opioids
containing a methylene spacer, showing molecular ion (4) and common
product ions (4a−4c).
Non-targeted Screening
In some ways, the development of new analytical approaches for
the detection of NPS is somewhat of an arms race, with forensic
toxicologists racing to keep up with the production of novel
compounds. From this perspective, methods that take a more
holistic approach to the detection of compounds structurally
related to known classes of NPS have the distinct advantages over
traditional targeted methods. These non-targeted approaches
are required for the detection and tentative identification
of novel analogs that have not been recorded previously
FIGURE 6 | Proposed structures of fragments observed for W series opioids,
showing molecular ion (5) and common product ions (5a−5c).
(Pasin et al., 2017a). Samples where these kinds of detections
arise can then be flagged for further confirmatory analysis when
appropriate CRMs are available. In this context, non-targeted
screening refers to the methods used for data acquisition, namely
DIA and DDA. When DIA is used, all precursor ions that reach
the detector are submitted to CID. On the other hand, DDA
involves the selection of a limited number of precursor ions for
CID, based on a set of user-defined criteria, which is determined
at the start of the experiment (Pasin et al., 2017a). Generally,
this data is compared to either in-house databases, which are
populated with information obtained from the previous analysis
of CRMs, or large online databases for compound identification
(Kinyua et al., 2015; Baz-Lomba et al., 2016; Pasin et al., 2017a).
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FIGURE 7 | Proposed structures of fragments observed for MT-45, showing
molecular ion (6) and product ions (6a−6d).
The diagnostic product ions identified in this work for each of
the different opioid classes can then be applied to filter through
this data to identify possible compounds of interest. A summary
of the different diagnostic ions for each opioid class can be
found in Table 1. This approach relies on the use of MS/MS
(sometimes referred to as MS2) data, therefore the effectiveness
of these data interpretation methods relies on the selection of an
appropriate data acquisition technique (Pasin et al., 2017a). Both
DIA and DDA techniques can be used for this purpose, however
DIA is less likely to result in the loss of data which might be
TABLE 1 | Summary of diagnostic product ions for each subclass of synthetic
opioids.































































*Refer to Figures 3–6.
relevant to the compounds of interest. Since DDA methods have
a limited number of precursor ions selected for CID, it is possible
that the compound/s of interest may not be subjected to CID,
especially when there are a number of abundant endogenous
compounds in the matrix being analyzed. While the number of
selected precursor ions can be increased, this can be limited by
the scan rate and data processing capabilities of the instrument
used (Pasin et al., 2017a).
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Using simple data processing methods, namely EICs and
neutral loss filtering (NLF), the identified product ions can be
used to detect the presence of different synthetic opioids in
complex samples. These techniques can be applied manually,
however many data processing software packages allow for the
automation of these processes. NLF calculates themass difference
between the product ions identified and the precursor ion. The
samples can then be interrogated for compounds that contain
these specific mass losses. This technique can be a useful adjunct
to EICs in situations where the product ions contain variable R
groups, meaning that their m/z values will vary, but the neutral
molecule which is lost has a consistent mass. For many of the
synthetic opioids, this technique has limited value, since many
of the neutral losses also contain R groups and, therefore, the
exact mass loss will vary. A group where NLF may prove useful
are the NPFs that contain side chains at the carbon-9 position of
the piperidine ring (Figure 2). All of the common product ions
identified for these compounds have R groups present, however,
the proposed structure for fragment 1a arises from the loss of the
C9 side chain. In all the compounds analyzed from this group,
the side chain consisted of either an ether or ester group with
masses of 59.0497 or 73.0290 Da, respectively. In this case, it may
be useful to target these two neutral losses to indicate the presence
of one of these compounds.
It is important to note, however, that NLF can be more
easily applied to data collected using DDA methods, rather
than DIA. As reported by Oberacher and Arnhard (2016), the
use of DIA leads to the production of chimeric spectra where
the software cannot associate product ions with their correct
precursor ions and, therefore, neutral losses cannot be calculated.
While deconvolution algorithms may be available to help sift
through the data, DDAdata does not require this extra processing
step and, therefore, may benefit more from the use of NLF. These
chimeric spectra do not limit the use of diagnostic product ions,
however, since all the product ions created will still be present in
the spectra. Since some product ions with consistent m/z values
have been identified for the different groups, with the exception
of the NPFs discussed previously, the use of EICs to target these
FIGURE 8 | Extracted Ion Chromatograms for diagnostic product ions
105.0704 (top) and 188.1439 (bottom) showing the identification of acetyl
fentanyl and fentanyl in a mixed sample.
diagnostic product ions may be the most effective way to detect
their presence in unknown samples.
Figure 8 shows the EICs for the diagnostic product ions
identified with m/z values of 105.0704 and 188.1439. These
product ions were found to be common to NPFs containing a
phenethyl tail and lacking any substitution at the C9 position of
the piperidine ring (Figure 3). It can be seen from these EICs
that there are two peaks at 5.5 and 5.85min which indicate
the presence of acetyl fentanyl A2 and fentanyl A1 (Figure 1),
respectively. For the purpose of this proof-of-concept sample,
the MS/MS spectra of the identified peaks were observed and
the retention times were compared to a targeted reporting
method to confirm the identities of the compounds detected. As
mentioned previously, a fragment with an m/z value of 105.0704
is quite common for alkyl-substituted benzenes, therefore, only
identifying a peak in this EIC may not be specific to NPFs and
requires further confirmation by the presence of other diagnostic
product ions or interrogation of the overall MS/MS spectra.
FIGURE 9 | Extracted Ion Chromatograms for diagnostic product ions
identified for the AH series opioids 144.9612, 172.9561, 189.9827, 201.9827,
284.0609 (A) and for the U series opioids 158.9768, 218.0140 and 298.0766
(B) showing the identification of AH-7921 and U-50488 in a mixed sample.
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Figure 9 shows additional EICs targeting the diagnostic
product ions for the AH opioids (3a−3e) and U series opioids
(4a−4c). For this sample, only the m/z values for fragments
containing 2 Cl substituents were used. It can be seen that these
EICs have indicated the presence of AH-7921 and U-50488 in
the sample, with retention times of 5.85 and 6.2min, respectively.
While there are multiple possible m/z values for these fragments
due to the different isotopes of Cl which may be present, the
detection of any one of these masses may indicate the presence
of one of these compounds in the sample being analyzed.
The concentration range of the spikes was evaluated in order
to determine an estimated limit of detection (LOD) for this
technique in a relevant biological matrix. It was found that,
down to a concentration of 0.05 ng/mL, the identified diagnostic
fragments could be clearly seen in the spiked samples. At lower
concentrations, some of the product ions no longer presented
peaks in their EICs, indicating that their abundance was too low
to accurately detect. While there were still some product ions
that could be detected at lower concentrations, the confidence
in the detection of a synthetic opioid would be reduced when
fewer diagnostic product ions are identified in a given sample.
In the case of fentanyl derivatives containing a phenylethyl tail
(Figure 3), if the product ion atm/z 188.1439 (Figure 8, bottom)
is not detected but the fragment atm/z 105.0704 can still be seen,
it may cast doubts as to the identity of the detected compound.
As previously stated, this fragment is common for any alkyl-
substituted aromatic compounds, therefore the specificity of
identifying this fragment alone would be limited.
The use of EICs to target common product ions for
the different groups of synthetic opioids can be useful for
the development of a non-targeted screening method. This
method does not rely on extensive MS databases or CRMs
to indicate the presence of these compounds. It should be
noted that this technique cannot be relied on in isolation and
should rather form part of a non-targeted screening workflow.
The detection of peaks related to the identified diagnostic
product ions can flag samples of interest, which may contain
forensically relevant compounds. The MS/MS spectra of the
detected peaks can be observed to identify the molecular ion of
interest and further, more targeted, analysis can be conducted
if necessary. The incorporation of techniques such as this into
non-targeted screening workflows can save forensic laboratories
time and resources by quickly flagging or eliminating samples
and reducing the use of superfluous techniques. This method
was applied to 157 race-day equine plasma samples taken
during the 2019 Autumn Carnival. While these samples have
all shown to be negative for synthetic opioids, it demonstrates
the ability of this technique to be incorporated alongside
routine analysis.
CONCLUSION
Various synthetic opioids, encompassing a number of different
subclasses, were subjected to CID using different CEs. A number
of different diagnostic product ions were identified for each
of the classes analyzed. These diagnostic product ions can be
incorporated into non-targeted screening strategies to detect
and tentatively classify these compounds without relying of
comparison to databases or CRMs.
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